ChartMill · Nov 19, 2026
Premarket Small-Cap Movers: Nov. 19, 2026 Gainers and Losers
Small-cap premarket movers for Nov. 19, 2026, including double-digit gainers and losers such as VIVS, SEAT, INHD, PIIIW, FCHL and AZI.
NASDAQ · SLS
Healthcare · Biotechnology
$14.86
Down-$3.09 (-17.21%)
Updated Nov 20, 2026, 2:38 AM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SLS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 19, 2026
SLS closed at $14.86 after 21 trading sessions, up 30.93% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | $15.38 | $16.5399 | $14.23 | $14.86 | 36.26M |
| Nov 18, 2026 | $19.51 | $21.40 | $17.22 | $17.95 | 35.75M |
| Nov 17, 2026 | $24.105 | $24.89 | $16.70 | $19.15 | 120.29M |
| Nov 16, 2026 | $7.74 | $8.39 | $7.235 | $7.47 | 7.97M |
| Nov 13, 2026 | $8.69 | $9.00 | $7.54 | $7.86 | 11.17M |
| Nov 12, 2026 | $8.16 | $8.405 | $8.00 | $8.03 | 4.38M |
| Nov 11, 2026 | $8.59 | $8.59 | $8.08 | $8.42 | 3.89M |
| Nov 10, 2026 | $8.32 | $8.80 | $8.08 | $8.37 | 3.93M |
| Nov 9, 2026 | $8.165 | $8.87 | $7.8136 | $8.58 | 4.79M |
| Nov 6, 2026 | $8.03 | $8.42 | $7.14 | $8.42 | 7.62M |
| Nov 5, 2026 | $9.005 | $9.05 | $7.83 | $7.88 | 10.74M |
| Nov 4, 2026 | $8.88 | $9.17 | $8.63 | $9.14 | 5.44M |
| Nov 3, 2026 | $8.72 | $9.18 | $8.57 | $8.87 | 5.05M |
| Nov 2, 2026 | $9.71 | $9.73 | $8.4801 | $8.55 | 14.42M |
| Oct 30, 2026 | $9.63 | $9.79 | $9.30 | $9.68 | 6.26M |
| Oct 29, 2026 | $10.42 | $11.0949 | $9.85 | $10.155 | 8.36M |
| Oct 28, 2026 | $12.20 | $12.44 | $9.705 | $10.38 | 23.77M |
| Oct 27, 2026 | $11.33 | $12.29 | $11.25 | $12.17 | 6.22M |
| Oct 26, 2026 | $11.535 | $11.70 | $11.18 | $11.34 | 3.21M |
| Oct 23, 2026 | $11.29 | $11.59 | $11.08 | $11.54 | 3.28M |
| Oct 22, 2026 | $11.91 | $12.37 | $11.12 | $11.35 | 6.51M |
The latest Smart Investors Daily articles mentioning SLS.
Company
Market Activity
Research & News
SLS research
Company profile and research snapshot.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 16, 2025 | Maxim Group | Buy | — |
| Nov 22, 2023 | Cantor Fitzgerald | Overweight | — |
| Sep 7, 2023 | Cantor Fitzgerald | Overweight | — |
| Nov 15, 2022 | Alliance Global Partners | Buy | — |
| Jun 28, 2022 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
ChartMill · Nov 19, 2026
Small-cap premarket movers for Nov. 19, 2026, including double-digit gainers and losers such as VIVS, SEAT, INHD, PIIIW, FCHL and AZI.
Benzinga · Nov 19, 2026
U.S. stock futures rose, but NetEase slid 5.2% after missing Q3 earnings and sales estimates; Red Robin and Sellas also fell sharply premarket.
Benzinga · Nov 19, 2026
Gainers SciSparc (NASDAQ:SPRC) stock increased by 62.9% to $0.44 during Thursday's pre-market session. Pulmatrix (NASDAQ:PULM) stock rose 13.58% to $1.52. The company's market cap stands at $4.8 million. As
Benzinga · Nov 19, 2026
Palo Alto Networks surged 9.1% after beating Q1 estimates and issuing strong Q2 guidance; several stocks rose while others fell premarket.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning SLS.